Thursday, August 28, 2014

Michael Perry joins Avita Medical board

February 6, 2013 by · Leave a Comment 

Avita Medical Ltd. (ASX:AVH; OTCQX:AVMXY) has appointed Dr. Michael Perry to its board. Dr. Perry is VP and senior global program head, Stem Cell Therapy, at Novartis Pharmaceuticals, and has over 25 years of pharmaceutical/biotech management and development experience.

BOD“Michael brings a wealth of experience and scientific acumen as well as the insights that come from running successful large global divisions and emerging start-ups,” Avita CEO Dr. William Dolphin said in a statement. “Michael will be a great addition to our board and I am delighted to be working with him.”

Dr. Perry said Avita has the potential to make a significant impact in the field of regenerative medicine. “I look forward to sharing my experiences and contributing to the future direction and growth at this early stage in the company’s history.”

Print Friendly

Comments are closed.

Email Newsletters with Constant Contact
Google+